GlassScriptPhysician profile
Asish Regmi
NPI 1659724334
$2,196.21
in general payments reported to CMS, 2019-2025
21 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $258 · 2024: $1,081 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.93 |
| Education | $254.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $311.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.57 | 2023-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $282.21 | 2023-2025 | Filspari |
| Amgen INC. | $259.93 | 2024-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $219.35 | 2023-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $143.66 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $105.71 | 2024-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $71.52 | 2024-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.39 | 2024 | Jardiance |
| Lilly USA, LLC | $62.34 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $61.28 | 2023 | Krystexxa |
| Scpharmaceuticals INC. | $59.48 | 2025 | |
| Ardelyx, INC. | $57.20 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $45.34 | 2024 | Veltassa |
| Calliditas Therapeutics US INC. | $28.73 | 2025 | Tarpeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $28.61 | 2023-2024 | Purified Cortrophin Gel |
| Vantive US Healthcare LLC | $22.11 | 2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $18.80 | 2023 | Velphoro |
| Glaxosmithkline, LLC. | $17.95 | 2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $17.73 | 2025 | Acthar |
| Idorsia Pharmaceuticals US INC | $16.53 | 2025 | Tryvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asish Regmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.